ROCK race on as Altheon takes glaucoma candidate into Phase II
This article was originally published in Scrip
Executive Summary
The private US firm Altheos has taken a step forward in the race to develop novel inhibitors of Rho kinase (ROCK) for the treatment of glaucoma with the start of a US Phase IIa trial for its lead project, ATS907.